Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 685

Sort by

Sort Order Select

Journal Articles

Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD

Xuezhi Hong, Yanhua Xiao, Liyan Xu, Lichong Shen, Ranjana Neelagar, Veda Devakumar, Thuong Trinh-Minh, Minrui Liang, Aleix Rius Rigau, Yun Zhang, Yi-Nan Li, Clara Dees, Andrea-Hermina Györfi, Daniel Wolff, Wolfgang Herr, Georg Schett, Jörg H. W. Distler, Alexandru-Emil Matei

Blood Adv (2025) 9 (6): 1261–1266.

https://doi.org/10.1182/bloodadvances.2024014387

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Haplo-Donor Age on Transplant Outcomes: A Comparative Analysis of Haploidentical vs Cord Blood Transplantation

Blood Adv bloodadvances.2024014938.

https://doi.org/10.1182/bloodadvances.2024014938

Published: 2025

Includes: Supplemental data

Journal Articles

Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

Blood Adv bloodadvances.2024015335.

https://doi.org/10.1182/bloodadvances.2024015335

Published: 2025

Includes: Supplemental data

Journal Articles

Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR Analysis

Blood Adv bloodadvances.2024014858.

https://doi.org/10.1182/bloodadvances.2024014858

Published: 2025

Includes: Supplemental data

Journal Articles

Antibiotic Use: Impact on the Microbiome and Cellular Therapy Outcomes

Alicia Darwin, Jiayi Xie, Melody Smith

Blood Adv bloodadvances.2024013809.

https://doi.org/10.1182/bloodadvances.2024013809

Published: 2025

Journal Articles

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma

Nadeem Tabbara, Marianna Zahurak, Cole H. Sterling, Iris Margalit Trutzer, Jaroslaw Jedrych, Lode J. Swinnen, Ephraim J. Fuchs, Javier Bolaños-Meade, Nina Wagner-Johnston, Richard J. Jones, Richard F. Ambinder, Ravi Varadhan, Suman Paul

Blood Adv (2025) 9 (5): 1202–1209.

https://doi.org/10.1182/bloodadvances.2024015048

Published: 2025

Includes: Supplemental data

Journal Articles

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis

Blood Adv (2025) 9 (5): 1040–1048.

https://doi.org/10.1182/bloodadvances.2024014374

Published: 2025

Includes: Supplemental data

Journal Articles

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease

Blood Adv (2025) 9 (5): 955–965.

https://doi.org/10.1182/bloodadvances.2024013926

Published: 2025

Includes: Supplemental data

Journal Articles

Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT

Veronica Bordoni, Federica Guarracino, Federica Galaverna, Valentina Bertaina, Giuseppina Li Pira, Marco Rosichini, Angela Pitisci, Giulia Matusali, Fabrizio Maggi, Enrico Velardi, Pietro Merli, Franco Locatelli, Chiara Agrati

Blood Adv (2025) 9 (5): 990–1002.

https://doi.org/10.1182/bloodadvances.2024013902

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma

Samer Al Hadidi, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Daisy Alapat, Guido Tricot, John Shaughnessy, Jr., Fenghuang Zhan, Jeffrey Sawyer, Eric R. Siegel, Bart Barlogie, Frits van Rhee, Maurizio Zangari

Blood Adv (2025) 9 (4): 950–953.

https://doi.org/10.1182/bloodadvances.2024014889

Published: 2025

Includes: Supplemental data

Journal Articles

Long-Term Outcomes and Quality of Life with Treosulfan-Based Conditioning in Hematological Malignancies

Rohtesh S. Mehta, Stephanie J. Lee, Ted A Gooley, Laurel Thur, Ann Dahlberg, Colleen Delaney, Boglarka Gyurkocza, Phuong T Vo, H. Joachim Deeg, Filippo Milano

Blood Adv bloodadvances.2024015392.

https://doi.org/10.1182/bloodadvances.2024015392

Published: 2025

Journal Articles

The transplant debate: defining innovation for sickle cell

Cécile Karsenty, Titilope Fasipe, Alexander I. Ngwube

Blood Adv (2025) 9 (4): 933–934.

https://doi.org/10.1182/bloodadvances.2024015400

Published: 2025

Journal Articles

Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?

Richard J. Jones, Adetola A. Kassim, Robert A. Brodsky, Michael R. DeBaun

Blood Adv (2025) 9 (4): 877–883.

https://doi.org/10.1182/bloodadvances.2024013693

Published: 2025

Journal Articles

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Blood Adv (2025) 9 (4): 752–758.

https://doi.org/10.1182/bloodadvances.2024014279

Published: 2025

Journal Articles

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

Blood Adv (2025) 9 (4): 741–751.

https://doi.org/10.1182/bloodadvances.2024014548

Published: 2025

Includes: Supplemental data

Journal Articles

Racial and socioeconomic status diversity and GVHD outcomes

Nosha Farhadfar, Stephanie J. Lee

Blood Adv (2025) 9 (3): 644.

https://doi.org/10.1182/bloodadvances.2024014712

Published: 2025

Journal Articles

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation

Nihar Desai, Majed Altareb, Mats Remberger, Carol Chen, Tommy Alfaro Moya, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Wilson Lam, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Rajat Kumar, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Jonas Mattsson, Arjun Datt Law

Blood Adv (2025) 9 (3): 660–669.

https://doi.org/10.1182/bloodadvances.2024014781

Published: 2025

Includes: Supplemental data

Journal Articles

PTCy unchained in matched siblings: the D is silent in GVHD

Nico Gagelmann, Anant Vatsayan

Blood Adv (2025) 9 (3): 670–671.

https://doi.org/10.1182/bloodadvances.2024015357

Published: 2025

Journal Articles

Post Transplant Cyclophosphamide as GvHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: the PHYLOS trial.

Blood Adv bloodadvances.2024015173.

https://doi.org/10.1182/bloodadvances.2024015173

Published: 2025

Includes: Supplemental data

Journal Articles

GVHD in the era of checkpoint inhibition in Hodgkin Lymphoma

Cecilia Anna Fidanza, Fabio Serpenti, Francesca Cavallaro, Kordelia Barbullushi, Nicolò Rampi, Francesca Gaia Rossi Dardanoni, Maria Cecilia Goldaniga, Giorgia Natascia Saporiti, Francesco Passamonti

Blood Adv bloodadvances.2025015912.

https://doi.org/10.1182/bloodadvances.2025015912

Published: 2025

NARROW

Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD

Impact of Haplo-Donor Age on Transplant Outcomes: A Comparative Analysis of Haploidentical vs Cord Blood Transplantation

Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR Analysis

Antibiotic Use: Impact on the Microbiome and Cellular Therapy Outcomes

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease

Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma

Long-Term Outcomes and Quality of Life with Treosulfan-Based Conditioning in Hematological Malignancies

The transplant debate: defining innovation for sickle cell

Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

Racial and socioeconomic status diversity and GVHD outcomes

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation

PTCy unchained in matched siblings: the D is silent in GVHD

Post Transplant Cyclophosphamide as GvHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: the PHYLOS trial.

GVHD in the era of checkpoint inhibition in Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only